Currency In USD
| Previous Close | 1.76 |
| Open | 1.8 |
| Day High | 1.81 |
| Day Low | 1.75 |
| 52-Week High | 4.46 |
| 52-Week Low | 1.04 |
| Volume | 3.88M |
| Average Volume | 7.32M |
| Market Cap | 614.38M |
| PE | -2.66 |
| EPS | -0.67 |
| Moving Average 50 Days | 1.96 |
| Moving Average 200 Days | 1.97 |
| Change | 0.02 |
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
GlobeNewswire Inc.
Mar 02, 2026 1:30 PM GMT
Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
GlobeNewswire Inc.
Jan 08, 2026 1:30 PM GMT
1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
GlobeNewswire Inc.
Dec 15, 2025 10:39 PM GMT
Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Fu